Specializing in the development of innovative drugs for the treatment of cardiovascular emergencies, particularly acute thrombotic diseases, Acticor Biotech is repositioning glenzocimab in the treatment of myocardial infarction.
IN MYOCARDINAL INFARCTIONS
In November 2022, Acticor Biotech announced the partnership with the University of Birmingham and announced the first clinical trial to test new drug glenzocimab for myocardial infarctions.
With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the UK: the Queen Elizabeth Hospital, Birmingham and the Northern General Hospital, Sheffield. This randomized, double-blind Phase 2b LIBERATE study will recruit more than 200 patients to test the tolerance and the efficacy of glenzocimab 1000 mg, versus placebo, to reduce heart damage following a myocardial infarction (MI), commonly known as a heart attack. Patient recruitment started on January 24th, 2024.
To date, 27 patients have been recruited, and study results are expected in Q4 of 2026.
The trial is running at the University of Birmingham with expert clinicians from the Institute of Cardiovascular Sciences and University Hospitals Birmingham NHS Foundation Trust. Bringing together experiences in running multi-site clinical trials from the Clinical Trial Units (CTU) and expertise in heart diseases, the team will see whether glenzocimab will reduce the amount of dead heart tissue in patients following an ST segment elevation myocardial infarction (STEMI), the most serious type of heart attack.